Discussing Patient Centricity’s Challenges and Opportunities

Posted by Pratap Khedkar on Wed, Jun 21, 2017

In my last blog post, I used the pharmaceutical industry’s quest for patient centricity as a jumping-off point to discuss how pharma companies need to focus on customer centricity, rethinking their commercial strategies to better address their many stakeholders in the evolving healthcare ecosystem. But since patients’ wellness is the pharmaceutical industry’s reason for being, patient centricity should remain pharma’s North Star. 


>
Read More

Patient Centricity Is Important, but Customer Centricity Is Imperative

Posted by Pratap Khedkar on Mon, May 01, 2017

Paul Darling co-authored this blog post with Pratap Khedkar.

Patient centricity was the rallying cry at last month’s eyeforpharma event in Philadelphia, with many speakers echoing the sentiment that the patient is at the center of what we do. That’s great in theory, and it has always been true for pharmaceutical products, but here’s one of the main reasons why patient centricity remains more of a talking point than standard business practice: The pharmaceutical industry has little control over ensuring that a patient benefits from a particular medicine. The patient may be at the center, but pharma is at the periphery.


>
Read More

My DC Visit Resulted in More Clarity Than Questions: Four Takeaways

Posted by Pratap Khedkar on Fri, Feb 10, 2017

Like so many millions of people—or so few, depending on whom you ask—I spent a couple of days in our nation’s capital during the Trump administration’s first week, but I wasn’t out on the National Mall with a cleverly worded sign. I was there to join other healthcare industry leaders, thought leaders and pundits as they discussed the evolving healthcare environment. I wanted to get a sense for what may be coming down the pike, and based on what I heard, it seems that the only constant is change—and pharmaceutical leaders better get ready to help shape this change. Here are four of my takeaways:


>
Read More

What Trump's Win Might Mean for Pharma

Posted by Pratap Khedkar on Tue, Dec 06, 2016

First, let’s acknowledge the obvious: Nobody knows what Trump’s win might mean for the pharma industry—not even Mr. Trump. Most presidential candidates outline detailed policies before an election, but as The Economist wrote in its Schumpeter column, “Mr. Trump arrives with a tatty envelope scrawled with a few jottings on the back.” At the same time, pharma stocks are up 10%, so the market sees this as good news.


>
Read More

Three Tips to Help Orchestrate Your Customer Experience

Posted by Pete Mehr on Fri, Apr 01, 2016

Healthcare practitioners (HCPs) today receive countless messages from pharmaceutical companies. In fact, data from our recent AffinityMonitor report estimates that the most valuable 30,000 HCPs receive 2,700-plus pharmaceutical contacts per year, equivalent to one contact per hour for 365 days.


>
Read More